Increasing access to cost-effective therapies
At Cencora, we believe in the promise of biosimilars to deliver cost savings across healthcare. We also understand the potential hurdles these unique products face. Together we can drive long-term stability in the marketplace and improve access to more cost-effective healthcare treatments for your patients.
Why partner with Cencora?
Cencora has provided distribution services for every biosimilar on the US market. As this market matures, its pipeline continues to grow.
100%
of FDA-approved biosimilars
are accessible through Cencora*
are accessible through Cencora*
$12.4B
est. healthcare savings due to the use of biosimilars
*Cencora has access to all FDA-approved biosimilar molecules but may not have access to all product versions inclusive of unbranded and/or private label. Cencora strives to provide the broadest access possible for providers and patients.
A product category with a promising future
Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. In order to capitalize on that promise, stakeholders across the healthcare ecosystem need to work together to stay ahead of approvals and foster an environment that enables increased access. We offer a variety of solutions to support pharma manufacturers through that process as well as services to assist healthcare providers in navigating the complicated biosimilars landscape.
For pharma manufacturers
A reliable partner to manufacturers committed to biosimilars
Our experts can help you devise channel strategies and tailored solutions for access and uptake. We offer market access consulting, distribution solutions, and patient support program services — as well as the Biosimilar Hub on our FormularyDecisions® platform, which facilitates the exchange of information between manufacturers and healthcare decision makers to help support the product evaluation process.
In addition to our distribution and commercialization services, we also provide market-leading reach into sites of care where patients are treated with biosimilars
For providers
Easier access to emerging therapies to improve patient care
Biosimilars are a promising product category, one that can enable providers to offer more affordable treatment options for their patients. Biosimilars undergo rigorous studies, receive FDA approval, and provide the same clinical results as their reference products.
As a healthcare professional, you can help patients understand that biosimilars are safe and effective treatment options that offer them the same outcomes as their reference products at potentially lower out-of-pocket costs.
As a healthcare professional, you can help patients understand that biosimilars are safe and effective treatment options that offer them the same outcomes as their reference products at potentially lower out-of-pocket costs.
Understanding the difference between generics and biosimilars
Biosimilars are not generics. Generics are exact copies of synthetic pharmaceuticals and the active ingredients must be the same as a brand name drug. Biosimilars are copies of biologics, which are medications made with living cells. They can have slight differences in clinically inactive components. The important thing to remember is there is no difference in how a biosimilar and its reference product treats its indicated condition.
Increased biosimilar adoption can improve medication access and affordability — enabling us to better support the patients we serve. Below, find a list of biosimilars available through Cencora in the US.
Featured resource
Connect with our biosimilars experts
Get in touch to learn how our solutions can help increase access to biosimilars. Whether you have questions or just need more information, our experts are here to assist you.